Shopping Cart
- Remove All
Your shopping cart is currently empty
Ilginatinib maleate (NS-018 maleate) is a highly active, orally bioavailable inhibitor of JAK2.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $41 | In Stock | |
| 5 mg | $98 | In Stock | |
| 10 mg | $137 | In Stock | |
| 25 mg | $201 | In Stock | |
| 50 mg | $289 | In Stock | |
| 100 mg | $413 | In Stock | |
| 200 mg | $548 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $109 | In Stock |
| Description | Ilginatinib maleate (NS-018 maleate) is a highly active, orally bioavailable inhibitor of JAK2. |
| Targets&IC50 | JAK2:0.72 nM, TYK2:22 nM, JAK3:39 nM, JAK1:33 nM |
| In vitro | Ilginatinib maleate(NS-018 maleate) is highly active against JAK2 with a 50% inhibition (IC(50)) of <1 n, and had 30-50-fold greater selectivity for JAK2 over other JAK-family kinases, such as JAK1, JAK3 and tyrosine kinase 2.?In addition to JAK2, NS-018 inhibited Src-family kinases.?NS-018 showed potent antiproliferative activity against cell lines expressing a constitutively activated JAK2 (the JAK2V617F or MPLW515L mutations or the TEL-JAK2 fusion gene;?IC(50)=11-120 n), but showed only minimal cytotoxicity against most other hematopoietic cell lines without a constitutively activated JAK2[1]. |
| In vivo | Ilginatinib maleate(NS-018 maleate) preferentially suppressed in vitro erythropoietin-independent endogenous colony formation from polycythemia vera patients.?NS-018 also markedly reduced splenomegaly and prolonged the survival of mice inoculated with Ba/F3 cells harboring JAK2V617F.?In addition, NS-018 significantly reduced leukocytosis, hepatosplenomegaly and extramedullary hematopoiesis, improved nutritional status, and prolonged survival in JAK2V617F transgenic mice.?suggest that NS-018 will be a promising candidate for the treatment of MPNs[1]. |
| Synonyms | NS-018 maleate |
| Molecular Weight | 505.5 |
| Formula | C25H24FN7O4 |
| Cas No. | 1354799-87-3 |
| Smiles | OC(=O)\C=C/C(O)=O.C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (98.91 mM), Sonication is recommended. H2O: < 0.1 mg/mL (insoluble) | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.96 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.